[HTML][HTML] Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice …

C Van Poznak, MR Somerfield, RC Bast… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
C Van Poznak, MR Somerfield, RC Bast, M Cristofanilli, MP Goetz, AM Gonzalez-Angulo…
Journal of clinical oncology, 2015ncbi.nlm.nih.gov
Purpose To provide recommendations on the appropriate use of breast tumor biomarker
assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A
literature search and prospectively defined study selection identified systematic reviews,
meta-analyses, randomized controlled trials (RCTs), prospective–retrospective studies, and
prospective comparative observational studies published from 2006 through September
2014. Results The literature search revealed 17 articles that met criteria for further review: 11 …
Abstract
Purpose
To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer.
Methods
A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective–retrospective studies, and prospective comparative observational studies published from 2006 through September 2014.
Results
The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective–retrospective studies that evaluated the clinical utility of biomarkers.
ncbi.nlm.nih.gov